Gut Dysfunction and Non-alcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) has emerged as one of the leading liver diseases worldwide. NAFLD is characterised by hepatic steatosis and may progress to an inflammatory condition termed non-alcoholic steatohepatitis, (NASH), liver cirrhosis and hepatocellular carcinoma. It became evident in the last years that NAFLD pathophysiology is complex and involves diverse immunological and metabolic pathways. An association between intestinal signals (e.g. derived from the gut microbiota) and the development of obesity and its metabolic consequences such as NAFLD are increasingly recognized. Preclinical studies have shown that germ-free mice are protected against obesity and hepatic steatosis. Several human studies from the past years have demonstrated that NAFLD contains a disease-specific gut microbiome signature. Controlled studies propose that certain bacteria with rather pro-inflammatory features such as Proteobacteria or Escherichia coli are dominantly present in these patients. In contrast, rather protective bacteria such as Faecalibacterium prausnitzii are decreased in NAFLD patients. Furthermore, various bacterial metabolites and microbiota-generated secondary bile acids are involved in NAFLD-associated metabolic dysfunction. Although these findings are exciting, research currently lack evidence that interference at the level of the gut microbiome is beneficial for these diseases. Further preclinical and clinical studies are needed to advance this aspect of NAFLD research and to support the notion that the intestinal microbiota is indeed of major relevance in this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk
Tang, W. H. W., Wang, Z., Levison, B. S., Koeth, R. A., Britt, E. B., Fu, X., Wu, Y., & Hazen, S. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109400 · Cited by 3,400
Gut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115
Current understanding of the human microbiome
Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018) · Nature Medicine · doi:10.1038/nm.4517 · Cited by 2,609
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
The gut microbiota and host health: a new clinical frontier
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309990 · Cited by 2,302
Diet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
Inflammatory mechanisms linking obesity and metabolic disease
Saltiel, A. R., & Olefsky, J. M. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92035 · Cited by 2,212 · cited 1×
“Indeed, insulin resistance has long been assumed to be controlled by inflammatory pathways (83).”
BackgroundButyrate improves insulin sensitivity and increases energy expenditure in mice
Gao, Z., Yin, J., Zhang, J., Ward, R. E., Martin, R. J., Lefevre, M., Cefalu, W. T., & Ye, J. (2009) · Diabetes · doi:10.2337/db08-1637 · Cited by 2,204 · cited 1×
“Butyrate is also suppressing HFD-induced obesity and insulin resistance (59).”
BackgroundFeuerer, M., Herrero, L., Cipolletta, D., Naaz, A., Wong, J., Nayer, A., Lee, J., Goldfine, A. B., Benoist, C., Shoelson, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.2002 · Cited by 2,145
Human gut microbes impact host serum metabolome and insulin sensitivity
Pedersen, H. K., Gudmundsdottir, V., Nielsen, H. B., Hyotylainen, T., Nielsen, T., Jensen, B. A. H., Forslund, K., Hildebrand, F., Prifti, E., Falony, G., et al. (2016) · Nature · doi:10.1038/nature18646 · Cited by 2,116 · cited 4×
“Similar to the Pedersen study (44), a recent report also observed that patients with pre-diabetes exhibit an aberrant intestinal microbiota accompanied by a decrease of A.”
BackgroundResultInfluentialRisk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755
Self-citationZhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434 · cited 1×
“One bacterial product which seems of key importance is endotoxin, which is elevated in advanced NAFLD (94, 95).”
BackgroundCause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells
Cipolletta, D., Feuerer, M., Li, A., Kamei, N., Lee, J., Shoelson, S. E., Benoist, C., & Mathis, D. (2012) · Nature · doi:10.1038/nature11132 · Cited by 1,143
Enterotypes in the landscape of gut microbial community composition
Costea, P. I., Hildebrand, F., Arumugam, M., Bäckhed, F., Blaser, M. J., Bushman, F. D., de Vos, W. M., Ehrlich, S. D., Fraser, C. M., Hattori, M., et al. (2017) · Nature Microbiology · doi:10.1038/s41564-017-0072-8 · Cited by 1,138
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
Sun, L., Xie, C., Wang, G., Wu, Y., Wu, Q., Wang, X., Liu, J., Deng, Y., Xia, J., Chen, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0222-4 · Cited by 1,011
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Self-citationHyperglycemia drives intestinal barrier dysfunction and risk for enteric infection
Thaiss, C. A., Levy, M., Grosheva, I., Zheng, D., Soffer, E., Blacher, E., Braverman, S., Tengeler, A. C., Barak, O., Elazar, M., et al. (2018) · Science · doi:10.1126/science.aar3318 · Cited by 942 · cited 2×
“Hyperglycemia impairs epithelial integrity (46) and could exhibit a relevant factor influencing composition of the intestinal microbiota.”
BackgroundMudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“Many more studies have demonstrated in the past years that bile acids and derivates are crucial metabolic players and interference at the level of FXR could indeed reflect a promising treatment strategy for NAFLD in the future (93).”
BackgroundIntestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749 · cited 2×
“First reports assessing the gut microbiome in NAFLD patients were presented a few years ago (32, 33).”
BackgroundMolecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Hoyles, L., Fernández-Real, J.-M., Federici, M., Serino, M., Abbott, J., Charpentier, J., Heymes, C., Luque, J. L., Anthony, E., Barton, R. H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0061-3 · Cited by 720 · cited 1×
“A large study assessed the relationship between metabolome, the gut microbiome and hepatic transcriptome (71).”
BackgroundDel Chierico, F., Nobili, V., Vernocchi, P., Russo, A., De Stefanis, C., Gnani, D., Furlanello, C., Zandonà, A., Paci, P., Capuani, G., et al. (2017) · Hepatology · doi:10.1002/hep.28572 · Cited by 696
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666
Insights into the role of the microbiome in obesity and type 2 diabetes
Hartstra, A. V., Bouter, K. E. C., Bäckhed, F., & Nieuwdorp, M. (2015) · Diabetes Care · doi:10.2337/dc14-0769 · Cited by 641 · cited 1×
“Overall, evidence is evolving that there exists similar to obesity (40) and type 2 diabetes (41) a “gut microbiotal signature” in NAFLD which might allow us in the future to differentiate between patients with simply fatty liver and NASH and might furthermore allow to elucidate underlying pathomechanisms in the develo…”
BackgroundHow Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560 · cited 1×
“This is potentially of major biological relevance as GPCRs are expressed by many cell types throughout the body and exert mainly immune and metabolic functions (50, 51).”
BackgroundCommensal bacteria make GPCR ligands that mimic human signalling molecules
Cohen, L. J., Esterhazy, D., Kim, S.-H., Lemetre, C., Aguilar, R. R., Gordon, E. A., Pickard, A. J., Cross, J. R., Emiliano, A. B., Han, S. M., et al. (2017) · Nature · doi:10.1038/nature23874 · Cited by 500 · cited 1×
“This is potentially of major biological relevance as GPCRs are expressed by many cell types throughout the body and exert mainly immune and metabolic functions (50, 51).”
BackgroundFukui, H., Brauner, B., Bode, J. C., & Bode, C. (1991) · Journal of Hepatology · doi:10.1016/0168-8278(91)90933-3 · Cited by 461
Puri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P. K., Cazanave, S., Luketic, V. A., Siddiqui, M. S., Boyett, S., Min, H., et al. (2018) · Hepatology · doi:10.1002/hep.29359 · Cited by 426
A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease
Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z. Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09455-9 · Cited by 338
Rau, M., Rehman, A., Dittrich, M., Groen, A. K., Hermanns, H. M., Seyfried, F., Beyersdorf, N., Dandekar, T., Rosenstiel, P., & Geier, A. (2018) · United European Gastroenterology Journal · doi:10.1177/2050640618804444 · Cited by 334
Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
Luther, J., Garber, J. J., Khalili, H., Dave, M., Bale, S. S., Jindal, R., Motola, D. L., Luther, S., Bohr, S., Jeoung, S. W., et al. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.01.001 · Cited by 286
Da Silva, H. E., Teterina, A., Comelli, E. M., Taibi, A., Arendt, B. M., Fischer, S. E., Lou, W., & Allard, J. P. (2018) · Scientific Reports · doi:10.1038/s41598-018-19753-9 · Cited by 283
Lelouvier, B., Servant, F., Païssé, S., Brunet, A., Benyahya, S., Serino, M., Valle, C., Ortiz, M. R., Puig, J., Courtney, M., et al. (2016) · Hepatology · doi:10.1002/hep.28829 · Cited by 242
Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes
Shan, Z., Sun, T., Huang, H., Chen, S., Chen, L., Luo, C., Yang, W., Yang, X., Yao, P., Cheng, J., et al. (2017) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.157107 · Cited by 210
Ahuja, M., Schwartz, D. M., Tandon, M., Son, A., Zeng, M., Swaim, W., Eckhaus, M., Hoffman, V., Cui, Y., Xiao, B., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.02.007 · Cited by 195
García‐Lezana, T., Raurell, I., Bravo, M., Torres‐Arauz, M., Salcedo, M. T., Santiago, A., Schoenenberger, A., Manichanh, C., Genescà, J., Martell, M., et al. (2018) · Hepatology · doi:10.1002/hep.29646 · Cited by 136
Cited by
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
Tilg, H., Adolph, T. E., & Moschen, A. R. (2021) · Hepatology · doi:10.1002/hep.31518 · Cited by 426
Self-citationLuci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
Hwang, S., Yun, H., Moon, S., Cho, Y. E., & Gao, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.751802 · Cited by 84
Metadata
- Authors
- Grabherr, F., Grander, C., Effenberger, M., Adolph, T. E., & Tilg, H.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-09-06
- Volume
- 10
- Pages
- 611-611
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2969631579
- Cited by
- 96
- References
- 41
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.